Scarica l'app Stockscreener
2.60
0.39%
0.01
Dopo l'orario di chiusura:
2.58
-0.02
-0.77%
Protalix BioTherapeutics Inc. Borsa (PLX) Ultime notizie
Virtu Financial LLC Has $64,000 Stock Holdings in Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
[Latest] Global Fabry Disease Treatment Market Size/Share Worth USD 7.02 Billion by 2034 at a 9.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value) - GlobeNewswire Inc.
Protalix Biotherapeutics is developing innovative treatments for rare diseases with its proprietary ProCellEx plant cell expression system - Proactive financial news
Protalix BioTherapeutics And 2 Other Promising Penny Stocks - simplywall.st
Protalix to present at iAccess Alpha Virtual Investment Conference 2025 - Proactive financial news
Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025 - Nasdaq
Exclusive Access: Protalix BioTherapeutics Reveals Growth Strategy at Premium Investor Summit - Stock Titan
Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now? - Insider Monkey
Nvidia, Nike, Sarepta Therapeutics, Protalix and more analyst calls of the week - Proactive financial news
Protalix Biotherapeutics chairman discusses breakthrough in gout treatment, drug pipelineICYMI - Proactive Investors USA
FY2025 Earnings Estimate for PLX Issued By Zacks Small Cap - Defense World
Protalix BioTherapeutics (NYSE:PLX) Stock Rating Lowered by StockNews.com - Defense World
Protalix Stock (PLX) Grabbing Attention with Record Revenue Surge - markets.businessinsider.com
Small cap wrap: Fineqia, Candel Therapeutics, Ocean Power Technologies, Protalix Biotherapeutics... - Proactive Investors UK
Protalix Biotherapeutics gains momentum: analysts see long-term upside - Proactive Investors USA
Protalix BioTherapeutics pipeline eyes gout treatment as financial strength fuels future growth - Proactive financial news
Protalix BioTherapeutics : Chiesi Global Rare Diseases Announces Multiple Presentations on pegunigalsidase alfa and Fabry Disease at the 21st Annual WORLDSymposium™ Research Meeting - Marketscreener.com
Protalix Biotherapeutics reports record revenue in 2024, advances gout treatment candidate - Proactive Investors UK
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q4 2024 Earnings Call Transcript - Insider Monkey
PLX: 2024 Results - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... - Yahoo
Protalix BioTherapeutics Inc (PLX) Q4 2024 Earnings Call Highlights: Record Revenue Growth ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Record Revenue and Clinical Progress - TipRanks
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth By Investing.com - Investing.com Canada
Protalix plans Phase 2 for PRX-115 in H2 2025, projects higher royalty revenues by 2030 - MSN
Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond - Benzinga
Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Earnings call transcript: Protalix Q4 2024 sees 31% revenue growth - Investing.com
Protalix BioTherapeutics Inc. (DE) (PLX) reports earnings - Quartz
Protalix Q4 Earnings Fall, Stock Up In Pre-market - Nasdaq
Protalix BioTherapeutics Reports Fiscal Year 2024 Financial and Business Results - GuruFocus.com
StockNews.com Upgrades Protalix BioTherapeutics (NYSE:PLX) to “Strong-Buy” - Defense World
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference - Kilgore News Herald
Protalix BioTherapeutics to Announce Fiscal Year 2024 Financial and Business Results on March 17, 2025 - Quantisnow
Protalix BioTherapeutics to Report FY2024 Earnings on March 17 - Stock Titan
Protalix BioTherapeutics (NYSE:PLX) and INmune Bio (NASDAQ:INMB) Head-To-Head Review - The AM Reporter
Protalix Biotherapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Y Intercept Hong Kong Ltd Acquires Shares of 18,818 Protalix BioTherapeutics, Inc. (NYSE:PLX) - Defense World
Protalix Biotherapeutics poised for profitability as rare disease drug gains momentum - Proactive financial news
Protalix BioTherapeutics Inc (PLX) Worth Considering For The Next Few Weeks - Stocks Register
H.C. Wainwright reiterates Protalix BioTherapeutics Inc (PLX) rating to a Buy - Knox Daily
Research Analysts Set Expectations for PLX FY2025 Earnings - MarketBeat
Q1 Earnings Forecast for PLX Issued By HC Wainwright - MarketBeat
Protalix BioTherapeutics (NYSE:PLX) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
Insider’s View: Deciphering Protalix BioTherapeutics Inc (PLX)’s Financial Health Through Ratios - The Dwinnex
Was Protalix BioTherapeutics Inc (PLX)’s session last reading good? - US Post News
What is HC Wainwright’s Forecast for PLX FY2024 Earnings? - Defense World
What is HC Wainwright's Estimate for PLX FY2024 Earnings? - MarketBeat
H.C. Wainwright lifts Protalix stock target to $15, maintains buy - MSN
Research Analysts Issue Forecasts for PLX Q1 Earnings - Defense World
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):